Cases & Deals

Celgene wins in district court case, invalidating patent asserted against its Thalomid® and Revlimid® brand cancer drugs

Clients Celgene Corporation

Jones Day successfully defended Celgene Corporation in a patent infringement case brought in the United States District Court for the District of Delaware by Andrulis Pharmaceuticals Corporation, which alleged that Celgene's THALOMID® and REVLIMID® brand cancer drugs infringed U.S. Patent No. 6,140,346 ("'346 patent"). After Jones Day obtained a ruling that the asserted '346 patent claim is indefinite, the plaintiff agreed that the asserted claim is invalid and stipulated to the entry of a final judgment of invalidity.

Andrulis Pharmaceuticals Corp. v. Celgene Corp., 1:13-cv-01644 (D. Del.)

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.